Skip to main content

and
  1. Article

    Open Access

    CSF p-tau increase in response to Aβ-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles

    Stephan A. Kaeser, Lisa M. Häsler, Marius Lambert, Carina Bergmann in Acta Neuropathologica (2022)

  2. Article

    Open Access

    Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

    Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer’s disease (AD), reflecting abnormal tau metabolism in the brain. Here we investigate the perfor...

    Shorena Janelidze, Erik Stomrud, Ruben Smith, Sebastian Palmqvist in Nature Communications (2020)

  3. Article

    Open Access

    Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser422 containing epitope on pathological tau

    Aggregation of tau protein and spreading of tau aggregates are pivotal pathological processes in a range of neurological disorders. Accumulating evidence suggests that immunotherapy targeting tau may be a viab...

    Jeroen van Ameijde, Rosa Crespo, Roosmarijn Janson in Acta Neuropathologica Communications (2018)

  4. Article

    Open Access

    A common antigenic motif recognized by naturally occurring human VH5–51/VL4–1 anti-tau antibodies with distinct functionalities

    Misfolding and aggregation of tau protein are closely associated with the onset and progression of Alzheimer’s Disease (AD). By interrogating IgG+ memory B cells from asymptomatic donors with tau peptides, we hav...

    Adrian Apetri, Rosa Crespo, Jarek Juraszek in Acta Neuropathologica Communications (2018)

  5. No Access

    Article

    Synthesis and Evaluation of a Zr-89-Labeled Monoclonal Antibody for Immuno-PET Imaging of Amyloid-β Deposition in the Brain

    The aim of this study was to evaluate the in vitro and in vivo characteristics of [89Zr]JRF/AβN/25, a radiolabeled monoclonal antibody directed against amyloid-β (Aβ).

    Jens Fissers, Ann-Marie Waldron, Thomas De Vijlder in Molecular Imaging and Biology (2016)

  6. Article

    Open Access

    Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors

    Cerebrospinal fluid (CSF) amyloid-beta (Aβ) peptides are predictive biomarkers for Alzheimer’s disease and are proposed as pharmacodynamic markers for amyloid-lowering therapies. However, frequent sampling res...

    Bianca Van Broeck, Maarten Timmers, Steven Ramael in Alzheimer's Research & Therapy (2016)

  7. Article

    Open Access

    APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment

    Alzheimer’s disease brains are characterized by extracellular plaques containing the aggregated amyloid β42 (Aβ42) peptide and intraneuronal tangles containing hyperphosphorylated tau. Aβ42 is produced by sequent...

    Simon Sjödin, Kerstin K. A. Andersson, Marc Mercken in Alzheimer's Research & Therapy (2015)

  8. Article

    Erratum to: Acute function of secreted amyloid precursor protein fragment APPsα in synaptic plasticity

    Meike Hick, Ulrike Herrmann, Sascha W. Weyer, Jan-Philipp Mallm in Acta Neuropathologica (2015)

  9. No Access

    Article

    Acute function of secreted amyloid precursor protein fragment APPsα in synaptic plasticity

    The key role of APP in the pathogenesis of Alzheimer disease is well established. However, postnatal lethality of double knockout mice has so far precluded the analysis of the physiological functions of APP an...

    Meike Hick, Ulrike Herrmann, Sascha W. Weyer, Jan-Philipp Mallm in Acta Neuropathologica (2015)

  10. Article

    Open Access

    Bexarotene treatment does not clear β-Amyloid in an AD mouse model and Beagle dogs

    Ina Tesseur, Adrian Lo, Anouk Roberfroid, Sofie Dietvorst in Molecular Neurodegeneration (2013)

  11. No Access

    Article

    The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

  12. The amyloid cascade hypothesis posits that the deposition of the amyloid-β peptide in the brain parenchyma is a crucial step in Alzheimer's disease (AD). This ...

  13. Eric Karran, Marc Mercken, Bart De Strooper in Nature Reviews Drug Discovery (2011)

  14. No Access

    Article

    Characterization of Aβ11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s disease

    Senile plaques (SPs), one of two defining lesions of Alzheimer’s disease (AD), are composed of a mixture of full-length Aβ1-40/42, and N- or C-terminally truncated Aβ peptides, including Aβ11-40/42. Sequential...

    Kangning Liu, Ingrid Solano, David Mann, Cynthia Lemere in Acta Neuropathologica (2006)

  15. No Access

    Article

    Extracellular amyloid formation and associated pathology in neural grafts

    Amyloid precursor protein (APP) processing and the generation of β-amyloid peptide (Aβ) are important in the pathogenesis of Alzheimer's disease. Although this has been studied extensively at the molecular and...

    Melanie Meyer-Luehmann, Martina Stalder, Martin C. Herzig in Nature Neuroscience (2003)

  16. Article

    No endogenous Aβ production in presenilin-deficient fibroblasts

    Omar Nyabi, Stefan Pype, Marc Mercken, An Herreman, Paul Saftig in Nature Cell Biology (2002)

  17. No Access

    Article

    Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

    Much evidence indicates that abnormal processing and extracellular deposition of amyloid-β peptide (Aβ), a proteolytic derivative of the β-amyloid precursor protein (βAPP), is central to the pathogenesis of Al...

    Christopher Janus, Jacqueline Pearson, JoAnne McLaurin, Paul M. Mathews in Nature (2000)

  18. No Access

    Article

    [32P]orthophosphate and [35S]methionine label separate pools of neurofilaments with markedly different axonal transport kinetics in mouse retinal ganglion cells in vivo

    Newly synthesized neurofilament proteins become highly phosphorylated within axons. Within 2 days after intravitreously injecting normal adult mice with [32P]orthophosphate, we observed that neurofilaments along ...

    Ralph A. Nixon, Susan E. Lewis, Marc Mercken, Ram K. Sihag in Neurochemical Research (1994)

  19. No Access

    Article

    Monoclonal antibodies with selective specificity for Alzheimer Tau are directed against phosphatase-sensitive epitopes

    A modified form of the microtubule-associated protein Tau is the major component of the paired helical filaments (PHF) found in Alzheimer's disease. The characterization of these posttranslational Tau modifica...

    Marc Mercken, Marc Vandermeeren, Ursula Lübke, Jan Six, Jef Boons in Acta Neuropathologica (1992)